Pharmasol Corporation – FDA 483, Aug 20, 2018
Pharmasol Corporation in South Easton, MA, a human drug manufacturer, received a Form FDA 483 with nine observations highlighting significant deficiencies in its quality system and manufacturing practices. Repeated observations from previous inspections indicate a persistent failure to adequately investigate discrepancies, follow quality control procedures, maintain stability testing programs, and ensure facility and equipment cleanliness. The findings suggest a systemic lack of control over critical processes, potentially impacting drug product quality and patient safety.
ID · 1def15f9-dbc9-4aa5-9c61-7173481cde23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.